In a major positive step for global respiratory health, Member States at the 78th World Health Assembly (WHA), held May 19–27 ...

The FDA delivered two notable approvals for RSV immunization, UroGen overcame a negative advisory committee vote to secure an ...

For the 2025-2026 respiratory viral season, Moderna intends to have mResvia available for both FDA-approved patient populations.

Research shows RSV leads to high hospitalization rates in adults, emphasizing the importance of enhanced surveillance and ...

Merck's Enflonsia vaccine for respiratory syncytial virus won approval from the Centers for Disease Control and Prevention's ...

The eight new ACIP members met for the first time June 25 after Kennedy fired all 17 original members of the committee June 9 ...

By a 5-2 vote, the Advisory Committee on Immunization Practices endorsed Merck’s Enflonsia for babies born during or entering their first RSV season.

In a move that has left many public health observers reeling, a newly appointed vaccine committee under Health and Human Services Secretary Robert F. Kennedy Jr. has voted to recommend an RSV shot for ...

The 2024-25 RSV season was the first in which the vaccine and the monoclonal antibody, which can prevent severe RSV lung infections in babies, were widely available.

RSV is a respiratory virus that infects the nose, throat and lungs. While people with larger airways and strong immune systems aren't as adversely affected by the infection, young children and ...

RSV is a respiratory virus that infects the nose, throat and lungs. While people with larger airways and strong immune systems aren't as adversely affected by the infection, young children and ...

A landmark global trial shows that one dose of the RSVPreF3 OA vaccine protects older adults against serious RSV lung disease for three seasons, raising hopes for long-term protection with just a ...